skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

Original Research

(2643) Views  (745) Full article downloads

Authors: David A Godfrey, Lee S Peplinski, Jeanette A Stewart, William C Stewart

Published Date January 2009 Volume 2009:3 Pages 189 - 194
DOI: http://dx.doi.org/10.2147/OPTH.S4741

David A Godfrey1, Lee S Peplinski2, Jeanette A Stewart3, William C Stewart3

1Glaucoma Associates of Texas, Dallas, TX, USA; 2Kentuckiana Institute for Eye Research, Louisville, KY, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USA

Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients.

Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes.

Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0–100 mm) at specified time intervals and a comfort survey.

Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 ± 16.2 mm) and travoprost BAK-free (7.8 ± 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P > 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P > 0.05).

Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.

Keywords: comfort, travoprost BAK-free, latanoprost, glaucoma, ocular hypertension






 

Other articles by Dr William Stewart



Readers of this article also read:

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency
Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
Erratum - Intracellular heavy metal nanoparticle storage
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
First experience with BAK-free travoprost 0.004% in topical glaucoma medication